Literature DB >> 20727764

CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival.

Isaac Yang1, Tarik Tihan, Seunggu J Han, Margaret R Wrensch, John Wiencke, Michael E Sughrue, Andrew T Parsa.   

Abstract

A growing body of evidence supports the significant interplay between the immune system and glioma pathogenesis. Here we investigate whether the extent of local glioma-associated CD8+ T-cell infiltrate at initial presentation correlates with long-term survival in patients with glioblastoma multiforme (GBM). The study was conducted by the University of California San Francisco Brain Tumor Research Center as part of the San Francisco Bay Area Adult Glioma Study, which included over 519 patients with GBM. A central neuropathology review was performed and populations of infiltrating CD8+ T-cells were quantified histologically. Of 108 patients studied, 43 patients had poor survival (<95days) and 65 patients had extended long-term survival of >403days. Tumors from long-term survivors were more likely than short-term survivors to have intermediate or extensive T-cell infiltrates compared to focal or rare infiltrates, and this association appears to be most significant in Caucasian women (p < 0.006). Thus, CD8+ T-cell infiltrate is associated with prolonged survival. Our data provide the impetus for more sophisticated studies to further elucidate prospectively the specific T-cell subtypes associated with long-term survival.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20727764      PMCID: PMC3064460          DOI: 10.1016/j.jocn.2010.03.031

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  52 in total

1.  PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme.

Authors:  A K Struss; B F Romeike; A Munnia; W Nastainczyk; W I Steudel; J König; H Ohgaki; W Feiden; U Fischer; E Meese
Journal:  Oncogene       Date:  2001-07-12       Impact factor: 9.867

2.  History of allergies among adults with glioma and controls.

Authors:  Joseph L Wiemels; John K Wiencke; Jennette D Sison; Rei Miike; Alex McMillan; Margaret Wrensch
Journal:  Int J Cancer       Date:  2002-04-01       Impact factor: 7.396

3.  Gliomas arising in organ transplant recipients: an unrecognized complication of transplantation?

Authors:  D Schiff; B O'Neill; E Wijdicks; J H Antin; P Y Wen
Journal:  Neurology       Date:  2001-10-23       Impact factor: 9.910

4.  History of allergies and autoimmune diseases and risk of brain tumors in adults.

Authors:  Alina V Brenner; Martha S Linet; Howard A Fine; William R Shapiro; Robert G Selker; Peter M Black; Peter D Inskip
Journal:  Int J Cancer       Date:  2002-05-10       Impact factor: 7.396

5.  Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.

Authors:  Robert M Prins; Sylvia K Odesa; Linda M Liau
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

6.  An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.

Authors:  John H Sampson; Gary E Archer; Duane A Mitchell; Amy B Heimberger; James E Herndon; Denise Lally-Goss; Sharon McGehee-Norman; Alison Paolino; David A Reardon; Allan H Friedman; Henry S Friedman; Darell D Bigner
Journal:  Mol Cancer Ther       Date:  2009-10       Impact factor: 6.261

Review 7.  Immunology and immunotherapy in neurosurgical disease.

Authors:  Robert M Prins; Linda M Liau
Journal:  Neurosurgery       Date:  2003-07       Impact factor: 4.654

8.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

Review 9.  EGFRvIII-targeted vaccination therapy of malignant glioma.

Authors:  Bryan D Choi; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Roger E McLendon; Darell D Bigner; John H Sampson
Journal:  Brain Pathol       Date:  2009-10       Impact factor: 6.508

Review 10.  The three Es of cancer immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

View more
  82 in total

1.  VSIG4 is highly expressed and correlated with poor prognosis of high-grade glioma patients.

Authors:  Tao Xu; Ying Jiang; Yong Yan; Hongxiang Wang; Chengyin Lu; Hanchong Xu; Weiqing Li; Da Fu; Yicheng Lu; Juxiang Chen
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

2.  Expression of antigen processing and presenting molecules in brain metastasis of breast cancer.

Authors:  Yan Liu; Yoshihiro Komohara; Natalie Domenick; Masasuke Ohno; Maki Ikeura; Ronald L Hamilton; Craig Horbinski; Xinhui Wang; Soldano Ferrone; Hideho Okada
Journal:  Cancer Immunol Immunother       Date:  2011-11-08       Impact factor: 6.968

3.  Absolute quantification of tumor-infiltrating immune cells in high-grade glioma identifies prognostic and radiomics values.

Authors:  A Reum Kim; Kyu Sung Choi; Min-Sung Kim; Kyung-Min Kim; Ho Kang; Sojin Kim; Tamrin Chowdhury; Hyeon Jong Yu; Chae Eun Lee; Joo Ho Lee; Soon-Tae Lee; Jae Kyung Won; Jin Wook Kim; Yong-Hwy Kim; Tae Min Kim; Sung-Hye Park; Seung Hong Choi; Eui-Cheol Shin; Chul-Kee Park
Journal:  Cancer Immunol Immunother       Date:  2021-01-08       Impact factor: 6.968

Review 4.  Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance.

Authors:  Olivera J Finn
Journal:  Exp Mol Pathol       Date:  2012-10-23       Impact factor: 3.362

5.  Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.

Authors:  Bryan D Choi; Chien-Tsun Kuan; Mingqing Cai; Gary E Archer; Duane A Mitchell; Patrick C Gedeon; Luis Sanchez-Perez; Ira Pastan; Darell D Bigner; John H Sampson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

Review 6.  The spectrum of vaccine therapies for patients with glioblastoma multiforme.

Authors:  Laura K Aguilar; Mariel Arvizu; Estuardo Aguilar-Cordova; E Antonio Chiocca
Journal:  Curr Treat Options Oncol       Date:  2012-12

7.  Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells.

Authors:  Smita K Nair; Gabriel De Leon; David Boczkowski; Robert Schmittling; Weihua Xie; Janet Staats; Rebecca Liu; Laura A Johnson; Kent Weinhold; Gary E Archer; John H Sampson; Duane A Mitchell
Journal:  Clin Cancer Res       Date:  2014-03-21       Impact factor: 12.531

8.  PD-1 blockade enhances the vaccination-induced immune response in glioma.

Authors:  Joseph P Antonios; Horacio Soto; Richard G Everson; Joey Orpilla; Diana Moughon; Namjo Shin; Shaina Sedighim; William H Yong; Gang Li; Timothy F Cloughesy; Linda M Liau; Robert M Prins
Journal:  JCI Insight       Date:  2016-07-07

9.  Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments.

Authors:  Yaoqing Shen; Cameron J Grisdale; Sumaiya A Islam; Pinaki Bose; Jake Lever; Eric Y Zhao; Natalie Grinshtein; Yussanne Ma; Andrew J Mungall; Richard A Moore; Xueqing Lun; Donna L Senger; Stephen M Robbins; Alice Yijun Wang; Julia L MacIsaac; Michael S Kobor; H Artee Luchman; Samuel Weiss; Jennifer A Chan; Michael D Blough; David R Kaplan; J Gregory Cairncross; Marco A Marra; Steven J M Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-30       Impact factor: 11.205

10.  Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-γ treatments: results from a multicentric study.

Authors:  Isabela J Wastowski; Renata T Simões; Layale Yaghi; Eduardo A Donadi; João T Pancoto; Isabelle Poras; Emmanuèle Lechapt-Zalcman; Myriam Bernaudin; Samuel Valable; Carlos G Carlotti; Sébastien Flajollet; Stine S Jensen; Soldano Ferrone; Edgardo D Carosella; Bjarne W Kristensen; Philippe Moreau
Journal:  Am J Pathol       Date:  2012-12-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.